

Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures

Wenguang Liu,¹ Satoru Toyosawa,² Tatsuya Furuichi,¹ Naoko Kanatani,¹ Carolina Yoshida,^{1,3} Yang Liu,¹ Miki Himeno,¹ Satoru Narai,⁴ Akira Yamaguchi,⁴ and Toshihisa Komori^{1,5}

¹Department of Molecular Medicine, Osaka University Medical School, Suita, Osaka 565-0871, Japan

²Department of Oral Pathology and ³Department of Orthodontics and Dentofacial Orthopedics, Osaka University Faculty of Dentistry, Suita, Osaka 565-0871, Japan

⁴Department of Oral Pathology, Nagasaki University School of Dentistry, Nagasaki 852-8588, Japan

⁵Japan Science and Technology Corporation, Kawaguchi City, Saitama Pref. 332-0012, Japan

Targeted disruption of *core binding factor α1* (*Cbfa1*) showed that *Cbfa1* is an essential transcription factor in osteoblast differentiation and bone formation. Furthermore, both in vitro and in vivo studies showed that *Cbfa1* plays important roles in matrix production and mineralization. However, it remains to be clarified how *Cbfa1* controls osteoblast differentiation, bone formation, and bone remodelling. To understand fully the physiological functions of *Cbfa1*, we generated transgenic mice that overexpressed *Cbfa1* in osteoblasts using type I collagen promoter. Unexpectedly, *Cbfa1* transgenic mice showed osteopenia with multiple fractures. Cortical bone, which was thin, porous, and enriched with osteopontin, was invaded by

osteoclasts, despite the absence of acceleration of osteoclastogenesis. Although the number of neonatal osteoblasts was increased, their function was impaired in matrix production and mineralization. Furthermore, terminally differentiated osteoblasts, which strongly express osteocalcin, and osteocytes were diminished greatly, whereas less mature osteoblasts expressing osteopontin accumulated in adult bone. These data indicate that immature organization of cortical bone, which was caused by the maturational blockage of osteoblasts, led to osteopenia and fragility in transgenic mice, demonstrating that *Cbfa1* inhibits osteoblast differentiation at a late stage.

Introduction

Bone is a mineralized tissue that is composed of an organic matrix. Type I collagen constitutes ~95% of the organic matrix, and the remaining 5% is composed of proteoglycans and noncollagenous proteins such as osteopontin and osteocalcin. Bone formation and maintenance are carried out by the coupled activities of osteoblasts and osteoclasts. Osteoblasts are bone-forming cells that synthesize and

mineralize extracellular matrix, whereas osteoclasts are bone-resorbing cells that remove mineralized matrix. Osteoblasts arise from multipotential mesenchymal cells and further differentiate into bone-lining cells and osteocytes, the latter of which are the most abundant cells in bone and work as mechanosensors (Nijweide et al., 1996). Osteoclasts are derived from hematopoietic precursor cells formed by the fusion of monocytic cells at the bone sites to be resorbed. Dysfunction of and imbalance between them can lead to bone metabolic disease states such as osteoporosis, which is marked by progressive bone loss and increased risk of fracture, or more rarely, osteopetrosis. Many factors influence the activities of these cells, and BMPs, TGFβs, FGFs, and IGFs, which are known to be local regulators of bone formation, have positive effects on osteoblast differentiation. Recent studies have suggested that many of them might target an important transcription factor, core binding factor α1 (*Cbfa1*)/runt-related gene (*Runx*)2, which

Address correspondence to Toshihisa Komori, Dept. of Molecular Medicine, Osaka University Medical School, 2-2 Yamada-oka Suita, Osaka 565-0871, Japan. Tel.: 81-6-6879-7590. Fax: 81-6-6879-7796. E-mail: komorit@imed3.med.osaka-u.ac.jp

*Abbreviations used in this paper: ALP, alkaline phosphatase; *Cbfa1*, core binding factor α1; HPRT, hypoxanthine guanine phosphoribosyl transferase; MMP, matrix metalloproteinase; OPG, osteoprotegerin; pQCT, quantitative computed tomography; RANKL, receptor activator of NF-κB ligand; RT, reverse transcriptase; *Runx*, runt-related gene; Tg, transgenic; TRAP, tartrate-resistant acid phosphatase; WT, wild-type.

Key words: *Cbfa1*; osteoblast; osteocyte; transgenic mice; osteopenia

directs a pathway in bone formation (for review see Yamaguchi et al., 2000).

Cbfa1 plays a pivotal role in osteogenesis (Komori and Kishimoto, 1998). Mice heterozygously mutated in the *Cbfa1* locus show a phenotype similar to that of cleidocranial dysplasia in humans, in whom mutations of *Cbfa1* have been found (Komori et al., 1997; Mundlos et al., 1997; Otto et al., 1997). A homozygous mutation of this gene in mice induced a complete lack of bone formation with arrest of osteoblast differentiation (Komori et al., 1997; Otto et al., 1997). However, the complete lack of osteoblasts and neonatal lethality makes it difficult to examine the postnatal function of *Cbfa1* by using this knockout model. An alternative model, which expressed the dominant negative form of *Cbfa1* (DN-*Cbfa1*), developed an osteopenic phenotype in mice and was used to indicate the indispensability of the gene for postnatal bone formation by regulating the functions of mature osteoblasts (Ducy et al., 1999). Furthermore, a large number of recent in vitro studies also implied that *Cbfa1* is a positive regulator that can upregulate the expression of bone matrix genes, including *type I collagen*, *osteopontin*, *bone sialoprotein*, *osteocalcin*, and *fibronectin*. (Banerjee et al., 1997; Ducy et al., 1997; Sato et al., 1998; Harada et al., 1999; Xiao et al., 1999; Kern et al., 2001; Lee et al., 2000; Prince et al., 2001). All of these studies have indicated that *Cbfa1* plays important roles in matrix formation and mineralization.

In the process of osteoblast differentiation, *Cbfa1* seems to function in the commitment of the osteoblast lineage from multipotential mesenchymal cells because *Cbfa1*-deficient calvarial cells had the potential to differentiate into both adipocytes and chondrocytes but completely lacked the ability to differentiate into the osteoblastic lineage (Kobayashi et al., 2000). However, after cells commit to the osteoblastic lineage it remains to be clarified how *Cbfa1* operates in the process of bone formation. To understand fully the functions of *Cbfa1* in the processes of osteoblast differentiation, matrix production, and mineralization, we generated transgenic mice that overexpress *Cbfa1* specifically in osteoblasts under the control of type I collagen promoter. Unexpectedly, *Cbfa1* transgenic mice showed severe osteopenia and suffered from bone fractures within a few weeks after birth. Osteopenia and fragility of bone were caused by the inhibition of osteoblast maturation, and immature osteoblasts accumulated in the bone of adult mice. These data indicate that *Cbfa1* inhibits the late stage of osteoblast maturation, restricting *Cbfa1*'s positive function to the early differentiation stage in the process of osteoblast development.

Results

Transgenic mice showed osteopenia with multiple fractures

The construct for *Cbfa1* transgenic mice was generated using the 2.3-kb proximal promoter of *pro- α 1(I) collagen* gene and type II *Cbfa1* cDNA, which starts from exon 1 (Enomoto et al., 2000), to express *Cbfa1* specifically in osteoblasts (Fig. 1 A) (Rossert et al., 1995). We also generated β -galac-




Figure 1. Generation of transgenic mice. (A) Diagrams of the DNA constructs used to generate *pro- α 1(I) collagen promoter Cbfa1* transgenic mice. DNA fragments covering the entire coding region of the mouse type II *Cbfa1* isoform and 2.3 kb *pro- α 1(I) collagen* gene promoter region were used. *SV40 splice donor/acceptor signals; **SV40 polyadenylation signal. (B and C) α -Galactosidase staining in *pro- α 1(I) collagen promoter α -galactosidase* transgenic mice at E15.5. (C) Longitudinal section of forelimb. Staining is observed specifically in osteoblasts around the diaphysis and in immature osteoblastic cells around the metaphysis. Sections were counterstained with eosin. (D) Northern blot hybridized with *Cbfa1* probe. RNA was extracted from tissues of 4-wk-old *Cbfa1* transgenic mice, and 20 μ g of total RNA was loaded per lane. St, stomach; Te, testis; Lu, lung; Sp, spleen; Li, liver; Th, thymus; Ki, kidney; He, heart; Br, brain; Mu, muscle; Bo, bone; Ca, cartilage; Sk, skin. (E) Northern blot analysis comparing the transgene and endogenous *Cbfa1* levels of expression in long bones of newborn *Cbfa1* transgenic mice. 20 μ g of total RNA was loaded. Bar, 100 μ m.

tosidase transgenic mice using the same *pro- α 1(I) collagen* promoter. The promoter directed the expression of the β -galactosidase gene to osteoblasts and immature osteoblastic cells (Fig. 1, B and C). Bone-specific expression of the transgene was confirmed also by Northern blot analysis using *Cbfa1* transgenic mice (Fig. 1 D). The transgene was expressed only in bone not in other tissues including muscle, brain, heart, kidney, thymus, liver, spleen, lung, testis, stomach, skin, and cartilage.

Although transgenic mice were born normally, they quickly started to display bone fractures (as early as 1 wk after birth), and within 3 wk most of them suffered from bone fracture. Bone fractures were found most frequently in tibiae, fibulae, calcanei, and femurs, whereas fractures in upper limbs and ribs were found also, indicating that the skeleton of transgenic mice was extremely fragile. Teeth of transgenic mice were also fragile and sometimes broken. The phenotype of teeth will be described elsewhere in detail. We generated seven F_0 transgenic mice with fractures. Although we succeeded in establishing a




Figure 2. Radiological analysis. (A–C) X-ray analysis of 6-wk-old *Cbfa1* transgenic mice from the established line. Whole skeletons of transgenic mice are proportionally shorter and more radiolucent (A). The transgenic mouse suffered from fractures in the tibia, fibula, and calcanei, and fracture healing is observed in these regions (A and B). The radiolucency is caused mainly by thinner cortices because metaphyseal trabeculation is similarly observed in femurs (C). (D) Radiograph of 9-wk-old F_0 transgenic mice. Whole skeletons are also more radiolucent, and fracture healing is observed in tibiae, fibulae, and calcanei in both lower limbs. WT, wild-type mouse; Tg, transgenic mouse.

line from one of them, the other F_0 mice were affected too severely to be bred and were analyzed directly. Although these F_0 mice suffered from severe fractures (Fig. 2 D), they showed phenotypes similar to the established line in radiological, histological, and Northern blot analyses, and the data from this line is described here in detail. The transgene expression of the line was about five times higher than endogenous *Cbfa1* expression (Fig. 1 E). The body weight of transgenic (Tg) mice became progressively lower than that of wild-type (WT) littermates during development and reached nearly half of the normal average value at 4 wk of age (Tg, male 9.4 ± 0.4 g, $n = 15$; Tg female, 9.2 ± 0.5 g, $n = 13$; WT, male 18.1 ± 0.4 g, $n = 61$; WT, female 15.2 ± 0.4 g, $n = 51$, $p < 0.01$). The fragility of bones and teeth seemed to cause the growth retardation. The serum concentration of calcium was similar between wild-type and transgenic mice at 6 wk of age

(WT, 9.5 ± 0.2 mg/dl, $n = 6$; Tg, 9.1 ± 0.2 mg/dl, $n = 9$, $P > 0.1$).

Radiological analysis showed that the whole skeleton of transgenic mice was proportionally shorter, and their bone was generally more radiolucent (Fig. 2, A and D). The fracture healing was observed in tibiae, fibulae, and calcanei, and cortices were thinner (Fig. 2, B and C). The histological appearance of tibiae clearly showed osteopenia in the transgenic mice (Fig. 3). The cortical bone of transgenic mice was porous and thinner at both 3 and 6 wk of age. The analysis by peripheral quantitative computed tomography (pQCT) also showed thinner cortical bone and enlarged marrow cavity in 3-mo-old transgenic mice (Fig. 4, A–E). The trabecular bone was decreased at 3 wk of age but not at 6 wk of age in transgenic mice (Fig. 3). This was also demonstrated by pQCT analyses in 3-mo-old mice, which showed similar amounts of mineral content in the






Figure 3. Histological appearance of transgenic bone. Longitudinal sections through the proximal tibia of wild-type (A and C) and transgenic (B and D) mice at 3 (A and B) and 6 wk of age (C and D). Cortical bone in transgenic mice is thin and porous at both 3 and 6 wk of age. Transgenic mice show reduced trabeculation at 3 wk of age but not at 6 wk of age. Undecalcified sections were stained with toluidine blue. Bar, 1 mm.

Figure 4. pQCT analysis. Diaphyses of femurs from wild-type and transgenic female mice at 3 mo of age were analyzed by pQCT. (A and B) pQCT images from wild-type (A) and transgenic (B) mice. Note the increased width of the marrow cavity and the concomitant reduction in cortical thickness in transgenic mice. Mineral densities are shown as different colors according to the standard mineral density gradients. (C–F) Cortical thickness (C), endosteal circumference (D), periosteal circumference (E), and bone mineral density (F) were measured for wild-type (white bars) and transgenic (black bars) mice. Error bars show means \pm SEM ($n = 4$). * $P < 0.05$ and ** $P < 0.01$ between wild-type and transgenic mice as determined by one-way ANOVA. Bars, 1 mm.



trabecular region (WT, 0.34 ± 0.02 mg/mm; Tg, 0.43 ± 0.04 mg/mm, $n = 4$, $P > 0.05$). Maintenance of trabecular bone and thinner porous cortical bone were observed also in histological analyses of 3- and 8-mo-old transgenic mice (unpublished data).



Cortical bone was immature and invaded by osteoclasts

Osteocytes in bone increase during growth. At 6 wk of age, both trabecular and cortical bone contained many osteocytes in wild-type mice but had few osteocytes in transgenic mice (Fig. 3 and Fig. 5, A and B). The drastic decrease of osteocytes was observed until 1 yr of age (Fig. 5, C–F; unpublished data). The decrease of osteocytes in transgenic mice is not due to cell death, since empty lacunae, which represent the death of osteocytes, were absent in bone. Numerous tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts were observed on the surface of trabecular bone but not in cortical bone of wild-type mice, whereas they were observed not only on trabecular bone

Figure 5. Decreased osteocytes, osteoclast invasion, collagen structure, and osteopontin deposition in cortical bone of transgenic mice. (A and B) TRAP staining of cortical bone in tibiae of wild-type (A) and transgenic (B) mice at 6 wk of age. Many TRAP-positive osteoclasts are observed in the cavities of cortical bone in transgenic mice (B). Note that osteocytes are diminished greatly in transgenic mice. (C and D) Polarized microscopy of cortical bone in tibiae of wild-type (C) and transgenic (D) mice at 3 mo of age. Cortical bone in transgenic mice shows the woven pattern instead of the lamellar collagen deposition seen in wild-type mice. (E and F) Immunohistochemical analysis in cortical bone of wild-type (E) and transgenic (F) mice at 3 mo of age using antiosteopontin antibody. Osteopontin is deposited heavily in cortical bone of transgenic mice. Note that osteocytes are spaced regularly in wild-type bone, but a few osteocytic cells are spaced irregularly in transgenic bone. Bars, 100 μ m.




Figure 6. Bone volume, matrix deposition, and cell parameters in *Cbfa1* transgenic mice. Trabecular bone volume (BV/TV; bone volume over tissue volume) (A), osteoid thickness (O.Th) (B), osteoblast number (N.Ob) (C), osteoblast surface (Ob.S) (D), osteocyte number (N.Ot) (E), osteoclast number (N.Oc) (F), osteoclast surface (Oc.S) (G), and eroded surface (ES) (H) are compared between wild-type (white bars) and transgenic mice (black bars) at 3 and 6 wk of age. The analyses were done using proximal parts of tibiae at secondary spongiosa except osteocyte number, which was counted at cortical bone of diaphysis. Bars show means \pm SEM ($n = 4$). * $P < 0.05$ and ** $P < 0.01$ between wild-type and transgenic mice as determined by one-way ANOVA.

but also on cortical bone, especially in the cavities in transgenic mice (Fig. 5, A and B). Polarization microscopy revealed that cortical bone of transgenic mice at 3 mo of age was composed mainly of immature bone, described as woven bone, in which collagen fibers ran in all directions, instead of mature lamellar bone, which has highly ordered parallel collagen fibers as seen in wild-type mice (Fig. 5, C and D). The composition of bone matrix was also different. Osteopontin protein was restricted to trabecular bone in wild-type mice, whereas it was distributed widely and extensively in the whole bone, including cortical bone, in transgenic mice (Fig. 5, E and F).

Osteoblast function was impaired in both matrix production and mineralization

The cause of osteopenia was examined in detail by histomorphometrical analyses at 3 and 6 wk of age. The trabecular bone volume (BV/TV) of transgenic mice was significantly decreased at 3 wk of age but not at 6 wk of age (Fig. 6 A). Although the number of osteoblasts in transgenic mice was more than twice that in wild-type mice at both 3 and 6 wk of age, matrix production by osteoblasts was impaired severely in transgenic mice as shown by the decreased thickness of newly deposited matrix (osteoid thickness; O.Th) (Fig. 6, B–D). Osteocytes were decreased dramatically in transgenic mice, with their number in cortical bone about one-tenth of that in wild-type mice (Fig. 6 E). The number of osteoclasts in the trabecular bone of transgenic mice was equivalent to that of wild-type mice, but osteoclasts in transgenic mice were less activated at 6 wk of age as shown by an $\sim 50\%$ decrease of osteoclast surface (Oc.S) and eroded surface (ES) (Fig. 6, F–H). Therefore, the maintenance of trabecular bone volume in 6-wk-old transgenic mice seems to be due to decreased osteolytic activity.


To perform kinetic analyses of bone formation and mineralization, calcein was injected twice at a 3-d interval in 3-wk-

old mice and a 7-d interval in 6-wk-old mice. Calcein injections formed two consecutive labels in most parts of 3- and 6-wk-old wild-type bone (Fig. 7 A). In contrast, transgenic bone showed only a single band of labeling or dual lines with decreased distance between them, and these bands were interrupted frequently by engraved cavities (Fig. 7 B). Trabecular dynamic histomorphometry was performed on the longitudinal sections of 3- and 6-wk-old bone. In transgenic mice, the mean distances between the two labels were short at both 3 and 6 wk of age (Fig. 7 C), and the mineralizing surface was decreased at 6 wk of age (Fig. 7 D), resulting in the significantly decreased bone formation rate at 6 wk of age (Fig. 7 E). Cortical dynamic histomorphometry was performed on cross sections of 3-wk-old bone. In transgenic mice, the mean distances between the two labels in both periosteum and endosteum were short (Fig. 7 F), and the mineralizing surface in periosteum was decreased (Fig. 7 G), resulting in the significantly decreased bone formation rates in both periosteum and endosteum (Fig. 7 H). Further, pQCT analysis showed that bone mineral density was decreased in the cortical bone of transgenic mice (Fig. 4 F). These data indicate that osteoblast function was impaired in both matrix production and mineralization in transgenic mice.

Fully differentiated osteoblasts were decreased and less mature osteoblasts were increased in transgenic mice

Because osteoblasts were increased but their function was impaired severely in transgenic mice, osteoblastic markers were investigated by in situ hybridization using probes of *type I collagen*, *osteopontin*, and *osteocalcin*. Mice at birth, 2 wk, 4 wk, 6 wk, 3 mo, and 8 mo of age were examined (Fig. 8; unpublished data). In wild-type mice at birth, most bone was covered by type I collagen-positive and osteopontin-positive

Figure 7. Bone formation in trabecular and cortical bone. To assess osteoblast function in mineralization, wild-type and transgenic mice were double labeled with calcein at 3 and 6 wk of age. (A and B) Fluorescent micrographs of the two labeled mineralization fronts in femurs of wild-type (A) and transgenic (B) mice at 3 wk of age. The distances between the double labeling in transgenic mice are much less than those of wild-type mice. Note that wild-type bone shows a clear double-labeling pattern, but transgenic bone shows waved single and double labeling with interruption. Cross sections of mid-diaphyses of femurs are shown. (C–E) Measurement of mineral apposition rate (MAR) (C), mineralizing surface (MS) (D), and bone forming rate (BFR) (E) in trabecular bone of wild-type (white bars) and transgenic (black bars) mice at 3 and 6 wk of age. Longitudinal sections from proximal parts of tibiae were used for the analysis. (F–H) Measurement of MAR (F), MS (G), and BFR (H) in periosteum and endosteum of wild-type (white bars) and transgenic (black bars) mice at 3 wk of age. Cross sections from mid-diaphyses of femurs were used for the analysis. Error bars show means \pm SEM ($n = 4$). * $P < 0.05$ and ** $P < 0.01$ between wild-type and transgenic mice as determined by one-way ANOVA. Scale bar, 100 μm .



cells, but the number of osteocalcin-positive cells was very low (Fig. 8, A, C, and E). In transgenic mice at birth, *osteopontin* was expressed strongly in type I collagen-positive cells, but osteocalcin was barely detectable (Fig. 8, B, D, and F). The number of type I collagen-positive cells was increased by >60% in transgenic newborns compared with their wild-type counterparts (WT, $1528 \pm 119/\text{mm}^2$; Tg, $2531 \pm 155/\text{mm}^2$, $n = 5$, $p < 0.01$). In wild-type mice, osteopontin-positive cells decreased gradually and osteocalcin-positive cells increased gradually during development, with osteocalcin-positive cells widely distributed at 3 mo of age (Fig. 8, K and M). However, in transgenic mice osteopontin-positive cells always covered most of the trabecular and cortical bone, but *osteocalcin* expression was much weaker than in their wild-type counterparts (Fig. 8, L, M, and N). Even in 8-mo-old transgenic mice, most bone was covered by osteopontin-positive cells, whereas only a small area of bone was covered by osteopontin-positive cells in the wild-type mice (unpublished data). Since osteopontin expression is detected earlier than osteocalcin expression in osteoblast differ-

entiation (Yoon et al., 1987; Mark et al., 1988), these data suggest that osteoblasts were less mature in transgenic mice.

Endogenous *Cbfa1* expression was also examined using a probe containing the 3' untranslated region, which does not hybridize with the transgene (Fig. 8, G, H, O and P; unpublished data). In wild-type mice, the expression pattern of *Cbfa1* was similar to that of *osteopontin* but different from that of *osteocalcin* at any age, although some overlaps of *Cbfa1* and *osteocalcin* expression were observed, especially at younger ages. It indicates that a major population of *Cbfa1* highly positive cells consists of less mature osteoblasts. In transgenic mice, endogenous *Cbfa1*-positive cells were increased, and the level of the expression seemed to be upregulated.

Cbfa1 failed to induce expression of the genes related to bone matrix, mineralization, and osteoclastogenesis

Expression of the genes related to bone matrix proteins, including *type I collagen*, *osteopontin*, *bone sialoprotein*, *osteocalcin*, and *matrix metalloproteinase (MMP)13*, is con-




Figure 8. Maturation stage of osteoblasts in *Cbfa1* transgenic mice. To determine the maturational stage of osteoblasts, sections from tibiae of wild-type (A, C, E, G, I, K, M, and O) and transgenic (B, D, F, H, J, L, N, and P) mice at birth (A–H) and 3 mo of age (I–P) were examined by in situ hybridization using type I collagen (A, B, I, and J), osteopontin (C, D, K, and L), osteocalcin (E, F, M, and N), and *Cbfa1* (G, H, O, and P) probes. The *Cbfa1* probe detects the expression of endogenous *Cbfa1* but not the transgene. Note that the pattern of *Cbfa1* expression is similar to that of *osteopontin* expression but not *osteocalcin* expression in wild-type mice (C, E, G, K, M, and O). *Osteopontin*-positive cells are increased markedly, but *osteocalcin* highly positive cells are decreased markedly in transgenic mice (K, L, M, and N). Ct, cortical bone; Tb, trabecular bone. Bars: (A–H) 200 μ m; (I–P) 100 μ m.

considered to be regulated by *Cbfa1* (Yamaguchi et al., 2000). *Alkaline phosphatase (ALP)* is considered to be up-regulated during osteoblast differentiation (Stein et al., 1990). To analyze the expression of these genes, Northern blot or reverse transcriptase (RT)-PCR analysis was performed using RNA from long bones of 1-mo-old wild-type and transgenic mice (Fig. 9). The expression of *pro- α 1 type I collagen* was decreased slightly in transgenic mice, whereas *pro- α 2 type I collagen* expression was similar between wild-type and transgenic mice. The expression of *osteopontin* and *bone sialoprotein* was increased but that of *ALP*, *osteocalcin*, and *MMP13* was decreased in transgenic mice. By using RT-PCR, we also examined the expression of *receptor activator of NF- κ B ligand (RANKL)* and *osteoprotegerin (OPG)*, which are important for osteoclastogenesis and osteoclast activity. In transgenic mice, OPG was decreased only slightly at 1 mo of age, but both RANKL and OPG were decreased clearly at 3 mo of age.




Figure 9. Expression of genes related to bone matrix, mineralization, and osteoclastogenesis. RNA was extracted from long bones without fractures at 4 wk of age for Northern blot analysis and at 4 and 11 wk of age for RT-PCR. 20 μ g of total RNA was loaded and hybridized with probes of *pro- α 1 (I) collagen (Col1(I))*, *osteocalcin (OC)*, *MMP13*, *ALP*, *bone sialoprotein (BSP)*, and *osteopontin (OP)*. *Glyceraldehyde-3-phosphate-dehydrogenase* was used as an internal control. Representative data from four independent samples are shown. The expression of *pro- α 2 (I) collagen (Col2(I))*, *RANKL*, and *OPG* was examined by RT-PCR. *HPRT* was used as an internal control. Duplicate PCRs were performed in four independent samples. Representative data are shown. WT, wild-type mouse; Tg, transgenic mouse.

Discussion

Cbfa1 transgenic mice showed severe osteopenia and suffered from multiple fractures. Although trabecular bone was conserved, cortical bone was reduced severely. Cortical bone, which is composed of immature bone with a few osteocytes, was invaded by osteoclasts. Enlarged bone marrow cavity also implied the osteolysis of cortical bone by osteoclasts. However, osteoclastogenesis was not accelerated in transgenic mice. Osteoblast number was increased from an early developmental stage, but osteoblast function was impaired in both matrix production and mineralization. Osteoblast maturation was inhibited at a late stage, and less mature osteoblasts accumulated to form the impaired bone in adult mice. Therefore, failure in the terminal differentiation of osteoblasts resulted in osteopenia and fragility in transgenic mice, demonstrating that *Cbfa1* inhibits osteoblast differentiation at a late stage.

Previous in vitro and in vivo data suggested that *Cbfa1* plays an important role in maturation of osteoblasts. However, our data showed that the late stage of osteoblast maturation was inhibited in transgenic mice as indicated by the accumulation of osteopontin-positive cells and the decrease of highly osteocalcin-positive cells, osteocytes, and *ALP* and *osteocalcin* expression. The accumulation of less mature osteoblasts in transgenic mice seemed to be caused not only by the maturational blockage of osteoblasts but also by acceleration of osteoblast differentiation at an early stage of cell development because osteoblasts were increased in number at neonatal stage (Fig. 8). Furthermore, the proliferation and apoptosis of less mature osteoblasts in transgenic mice have to be considered, although their analyses in vitro were unsuccessful because of the loss of the transgene expression in

primary culture of calvaria-derived cells (unpublished data) as previously described (Krebsbach et al., 1993).

ALP activity is detected at an early stage of osteoblast differentiation and continues to increase during osteoblast maturation until the mineralization phase (Stein et al., 1990; Weinreb et al., 1990). In vitro experiments demonstrated that *Cbfa1* transfection induced ALP activity in multipotential mesenchymal cells, C3H10T1/2 and C2C12 (Harada et al., 1999; Lee et al., 2000), indicating an important role for *Cbfa1* in the induction of ALP activity. Although the difference in ALP expression level between transgenic and wild-type mice was not apparent at birth, it became evident during development (Fig. 9; unpublished data). This suggests that overexpression of *Cbfa1* blocks osteoblast maturation at a certain stage in vivo.

Since osteocalcin expression is restricted to mature osteoblasts and odontoblasts, it is a convenient marker for fully differentiated osteoblasts (Mark et al., 1988; Stein et al., 1990). *Cbfa1* induced *osteocalcin* expression in various cells in vitro including MC3T3-E1, C3H10T1/2, and skin fibroblasts (Ducy et al., 1997; Harada et al., 1999). Furthermore, *Cbfa1* or related proteins bound osteocalcin promoter and strongly induced osteocalcin promoter activity in various cell lines, including C3H10T1/2 and nonosteoblastic cells, HeLa and F9, and *Cbfa1* binding sites, were essential for *osteocalcin* expression (Geoffroy et al., 1995; Banerjee et al., 1996; Frenzo et al., 1998; Javed et al., 1999; Xiao et al., 1999). These findings suggested that *Cbfa1* is the most important factor for osteoblast-specific *osteocalcin* expression in vitro. However, a major population of *Cbfa1* highly positive cells consisted of less mature osteoblasts in wild-type mice, and overexpression of *Cbfa1* failed to upregulate *osteocalcin* expression in vivo (Figs. 8 and 9). These data indicate that other factors, which are induced at a late stage of osteoblast differentiation, are required for the regulation of *osteocalcin* expression or that some factors suppress *osteocalcin* expression at an immature stage of osteoblast differentiation in vivo. It has been shown that Groucho/TLE proteins repress Runx-dependent activation of tissue-specific gene transcription (Levanon et al., 1998; Javed et al., 2000), and TLE downregulates *Cbfa1*-mediated activation of *osteocalcin* expression (Javed et al., 2000). Further, Runx1 is known to interact with the corepressor mSin3A (Lutterbach et al., 2000). Thus, these repressors may play an important role in the transcriptional regulation of *osteocalcin* by repressing *Cbfa1*-dependent activation at an early stage of osteoblast differentiation.

Overexpression of DN-*Cbfa1* at a late stage of osteoblast differentiation caused a decrease in the bone formation rate and decreased expression of the genes encoding main bone matrix proteins and resulted in osteopenia (Ducy et al., 1999). Surprisingly, our transgenic mice overexpressing *Cbfa1* at both early and late stages of osteoblast differentiation also showed an osteopenic phenotype, although the mechanism for osteopenia was different. The two kinds of transgenic mice had a common feature because *Cbfa1* function was suppressed in fully differentiated osteoblasts of DN-*Cbfa1* transgenic mice, and the fully differentiated osteoblasts were diminished in our *Cbfa1* transgenic mice. Therefore, both transgenic mice lacked at least *Cbfa1*-dependent function of fully differentiated osteoblasts, which finally caused osteopenia in both transgenic mice. It indicates that *Cbfa1* inhibits

osteoblast differentiation at a late stage, but some level of *Cbfa1* is required for the expression of the genes encoding main bone matrix proteins. It also indicates that the transcriptional regulation of bone matrix genes by *Cbfa1* is dependent on the maturational stage of osteoblasts as discussed about *osteocalcin* expression in the previous paragraph.

It was reported recently that RANKL is essential for osteoclastogenesis and that OPG inhibits osteoclastogenesis (Aubin and Bonnellye, 2000), and it was suggested that *Cbfa1* is involved in the regulation of *RANKL* or *OPG* expression (Gao et al., 1998; Kitazawa et al., 1999; Thirunavukkarasu et al., 2000). However, both *RANKL* and *OPG* decreased gradually during development in transgenic mice (Fig. 9). It was suggested that osteoprogenitor cells have more potential to support osteoclast development than more differentiated cells (Manolagas, 2000). Therefore, the decrease of *RANKL* may reflect the relative decrease of osteoprogenitor cells because *Cbfa1* seemed to accelerate the early stage of osteoblast differentiation (Fig. 8). In transgenic mice, cortical bone mass but not trabecular bone mass was reduced severely without acceleration of osteoclastogenesis. However, the enlarged bone marrow cavity and the presence of numerous osteoclasts in cortical bone showed that cortical bone loss was a result of osteolytic activity. This seemed to be caused by the immature composition of cortical bone, which contains abundant osteopontin with the small cell attachment motif Arg-Gly-Asp recognized by integrins and promotes the attachment of osteoclasts to the extracellular matrix (Fig. 5; Young et al., 1993). The expression of bone sialoprotein, which also has the Arg-Gly-Asp motif, was increased in Northern blot analysis (Fig. 9).

The drastic decrease of osteocytes that is a unique phenotype of the transgenic mice was caused by the inhibition of osteoblast maturation. Osteocytes are spaced regularly throughout the bone and communicate with each other and with osteoblasts and bone marrow stromal cells using their processes. Although the exact function of osteocytes remains unknown, they are considered to work as mechanosensors (Nijweide et al., 1996). Thus, the fragility of transgenic bone might be caused by the near absence of osteocytes, causing an inability to detect mechanical stress and microfractures.

Overexpression of *Cbfa1* in osteoblasts increased osteoblast number but inhibited their terminal maturation, resulting in accumulation of less mature osteoblasts and osteopenia. Therefore, in an attempt to increase bone mass by *Cbfa1* intermittent induction of *Cbfa1* in osteogenic cells might permit a periodic increase of immature osteoblasts and their maturation. This concept might be related to the anabolic action on bone mass induced by the intermittent administration of parathyroid hormone (Dempster et al., 1993; Ishizuya et al., 1997; Jilka et al., 1999) because parathyroid hormone induces a protein kinase A-dependent transactivation of *Cbfa1* (Selvamurugan et al., 2000).

We demonstrated using *Cbfa1* transgenic mice that *Cbfa1* negatively regulates osteoblast differentiation at a late stage of osteoblast development. However, *Cbfa1* seems to regulate osteoblast differentiation positively at an early stage. These opposite functions of *Cbfa1*, depending on the maturational stage of osteoblasts, may play an important role in the regula-

tion of bone mass. Since Cbfa1 is an essential factor for osteoblast differentiation, many factors and substances that have an effect on bone mass will influence Cbfa1 expression or activation. Thus, our findings are expected to be of great benefit to future trials to increase bone mass.

Materials and methods

Generation of transgenic mice

A DNA fragment covering the entire coding region of the mouse type II Cbfa1 isoform (Harada et al., 1999) was cloned into the mammalian expression vector pNASSB (CLONTECH Laboratories, Inc.) by replacing the β -galactosidase gene at NotI sites, giving rise to an intermediate vector for inserting a promoter. A DNA fragment containing the 2.3-kb osteoblast-specific promoter region for the mouse *pro- α 1 (I) collagen* (Rossert et al., 1995), which was provided by B. de Crombrugge (The University of Texas, Houston, Texas), was inserted into XhoI site of the intermediate vector to generate the final expression construct. The fragments from the final construct, including the 2.3-kb *pro- α 1 (I)* promoter and Cbfa1, were injected into the pronuclei of fertilized eggs from C57BL/6 \times C3H F₁ (B6C3H F₁) mice. Transgene integration and expression were identified by Southern and Northern blot analyses, respectively, using the whole length cDNA of type II Cbfa1 as a probe. A transgenic line was maintained on a B6C3H F₁ background.

Detection of β -galactosidase activity

To confirm the activity of the promoter used in this study, we also subcloned the DNA fragment covering the 2.3-kb *pro- α 1 (I)* promoter region into the EcoRI site of pNASSB to direct the expression of the β -galactosidase gene. The β -galactosidase transgenic embryos were analyzed at different days postcoitum. Detection of β -galactosidase activity was performed as described (Ueta et al., 2001). Stained embryos were embedded in paraffin and used to generate 7- μ m sections, which were counterstained with eosin.

X-ray and pQCT analyses

Transgenic mice and their wild-type littermates were anesthetized and subjected to x-ray exposure in a micro-FX1000 (Fuji Film, Inc.). Long bones were dissected from killed mice and exposed to x-rays. In pQCT analysis, femurs were fixed with 10% buffered formalin for 24 h and measured using an XCT Research SA (Stratec Medizintechnik). Voxel size was 0.08 \times 0.08 \times 0.46 mm. The contour of the total bone was determined automatically by the pQCT software algorithm. The cortical and trabecular parameters were obtained at the diaphysis and 2 mm from distal epiphysis, respectively. The threshold values of 690 mg/cm³ for the cortical region and 395 mg/cm³ for the trabecular region were used in this experiment.

Histological analyses

For histological analyses, mice were killed at birth, 2 wk, 3 wk, 4 wk, 6 wk, 3 mo, 8 mo, and 1 yr of age. For the assessment of dynamic histomorphometric indices, mice were injected twice with calcein at a dose of 0.16 mg/10 g body weight and analyzed at 3 or 6 wk of age. The 3-wk group received dual injections at 6 and 3 d before sacrifice, and the 6-wk group received them at 8 and 1 d before sacrifice. Long bones were fixed with ethanol, and the undecalcified bones were embedded in glycolmethacrylate. 3- μ m longitudinal sections from the proximal parts of tibiae and 20- μ m cross sections from mid-diaphyses of femurs were stained with toluidine blue and analyzed using a semiautomated system (Osteoplan II; ZEISS). Nomenclature, symbols, and units used are those recommended by the Nomenclature Committee of the American Society for Bone and Mineral Research (Parfitt et al., 1987). Some of the sections were stained with TRAP. Bones from the other mice were fixed in 4% paraformaldehyde/0.1 M phosphate buffer. Decalcified and paraffin-embedded sections (5 μ m thick) were used for the following analyses. To examine collagen fiber deposition, sections from tibiae were stained with hematoxylin and eosin and observed under polarized light (Bucay et al., 1998). To examine osteoblast markers, sections of tibiae at different ages were also used for *in situ* hybridization using probes for *type I collagen*, *osteopontin*, *osteocalcin*, and *Cbfa1* as described previously (Inada et al., 1999).

Immunohistochemistry

Paraffin sections were blocked with 1% BSA containing 10% swine or rabbit serum at room temperature for 20 min and then incubated with rabbit anti-mouse osteopontin antibody (IBL Co., Ltd.) overnight at 4°C. Localiza-

tion of the first antibody was visualized by incubation with biotinylated F(ab)₂ fragments of swine anti-rabbit IgG antibody (Dako) at room temperature for 40 min and then treated with the ABC reagents (Vector Laboratories). Finally, sections were stained by DAB substrate and counterstained with methyl green.

Northern blot and RT-PCR

Total RNA was extracted from long bones without fracture from newborn and 4- and 11-wk-old transgenic and wild-type mice by lithium chloride. 20 Mg of total RNA was denatured with formamide, subjected to electrophoresis on 1.0% agarose gels, and transferred onto nylon membranes. Membranes were hybridized with ³²P-labeled cDNA probes of *pro- α 1 (I) collagen*, *osteocalcin*, *MMP13*, *ALP*, *osteopontin*, *bone sialoprotein*, and *glyceraldehyde-3-phosphate-dehydrogenase* as described previously (Inada et al., 1999). For RT-PCR, cDNA was amplified by Amp Taq DNA polymerase (PerkinElmer) using the following primers: *Pro- α 2 (I) collagen*, 5'-TGTGCTTCTGCAGGGTCCA-3' and 5'-ACACGGAATCTTGGTC-AGC-3'; *RANKL*, 5'-GTCACCTGTCTCTTGGTAC-3' and 5'-TGAAC-CCCAAGTACGTCG-3'; *OPG*, 5'-CAGCTTCTGCCTTGATGGAGA-3' and 5'-AAACAGCCCAGTGACCATTCT-3'; *hypoxanthine guanine phosphoribosyl transferase (HPRT)*, 5'-GCTGGTAAAAGGACCTCT-3' and 5'-CACAGGACTAGAACAACTGC-3'. 18 (*pro- α 2 (I) collagen*), 27 (*RANKL*), 28 (*OPG*), and 23 cycles (*HPRT*) of amplification were done with a Gene Amp PCR system 2400 (Perkin Elmer) (30 s at 94°C, 30 s at 55 or 60°C, and 30 s at 72°C).

We thank M. Iwamoto for critical discussions, B. de Crombrugge for type I collagen promoter, H. Harada for Cbfa1 cDNA, H. Murayama (Kureha Chemical Industry) for bone histomorphometrical analysis, K. Nonaka (Elk Corporation) for pQCT analysis, R. Hiraiwa for maintaining mouse colonies, and R. Ohkawa for secretarial assistance.

This work was supported by grants from the Ministry of Education, Science, and Culture, Japan, and the Yamanouchi Foundation for Research on Metabolic Disorders.

Submitted: 9 May 2001

Revised: 25 July 2001

Accepted: 20 August 2001

References

- Aubin, J.E., and E. Bonnelly. 2000. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. *Osteoporos. Int.* 11:905–913.
- Banerjee, C., S.W. Hiebert, J.L. Stein, J.B. Lian, and G.S. Stein. 1996. An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. *Proc. Natl. Acad. Sci. USA.* 93:4968–4973.
- Banerjee, C., L.R. McCabe, J.Y. Choi, S.W. Hiebert, J.L. Stein, G.S. Stein, and J.B. Lian. 1997. Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. *J. Cell Biochem.* 66:1–8.
- Bucay, N., I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, et al. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes Dev.* 12: 1260–1268.
- Dempster, D.W., F. Cosman, M. Parisien, V. Shen, and R. Lindsay. 1993. Anabolic actions of parathyroid hormone on bone. *Endocr. Rev.* 14:690–709.
- Ducy, P., R. Zhang, V. Geoffroy, A.L. Ridall, and G. Karsenty. 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. *Cell.* 89:747–754.
- Ducy, P., M. Starbuck, M. Priemel, J. Shen, G. Pinero, V. Geoffroy, M. Amling, and G. Karsenty. 1999. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. *Genes Dev.* 13:1025–1036.
- Enomoto, H., M. Enomoto-Iwamoto, M. Iwamoto, S. Nomura, M. Himeno, Y. Kitamura, T. Kishimoto, and T. Komori. 2000. Cbfa1 is a positive regulatory factor in chondrocyte maturation. *J. Biol. Chem.* 275:8695–8702.
- Frendo, J.L., G. Xiao, S. Fuchs, R.T. Franceschi, G. Karsenty, and P. Ducy. 1998. Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression *in vivo*. *J. Biol. Chem.* 273:30509–30516.
- Gao, Y.H., T. Shinki, T. Yuasa, H. Kataoka-Enomoto, T. Komori, T. Suda, and A. Yamaguchi. 1998. Potential role of Cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). *Biochem. Biophys. Res. Commun.* 252:697–702.

- Geoffroy, V., P. Ducy, and G. Karsenty. 1995. A PEBP2 alpha/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. *J. Biol. Chem.* 270:30973–30979.
- Harada, H., S. Tagashira, M. Fujiwara, S. Ogawa, T. Katsumata, A. Yamaguchi, T. Komori, and M. Nakatsuka. 1999. *Cbfa1* isoforms exert functional differences in osteoblast differentiation. *J. Biol. Chem.* 274:6972–6978.
- Inada, M., T. Yasui, S. Nomura, S. Miyake, K. Deguchi, M. Himeno, M. Sato, H. Yamagiwa, T. Kimura, N. Yasui, et al. 1999. Maturational disturbance of chondrocytes in *Cbfa1*-deficient mice. *Dev. Dyn.* 214:279–290.
- Ishizuya, T., S. Yokose, M. Hori, T. Noda, T. Suda, S. Yoshiki, and A. Yamaguchi. 1997. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. *J. Clin. Invest.* 99:2961–2970.
- Javed, A., S. Gutierrez, M. Montecino, A.J. van Wijnen, J.L. Stein, G.S. Stein, and J.B. Lian. 1999. Multiple *Cbfa*/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. *Mol. Cell. Biol.* 19:7491–7500.
- Javed, A., B. Guo, S. Hiebert, J. Choi, J. Green, S. Zhao, M.A. Osborne, S. Stifani, J.L. Stein, J.B. Lian, et al. 2000. Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF β /AML/PEBP2 β) dependent activation of tissue-specific gene transcription. *J. Cell Sci.* 113:2221–2231.
- Jilka, R.L., R.S. Weinstein, T. Bellido, P. Roberson, A.M. Parfitt, and S.C. Manolagas. 1999. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. *J. Clin. Invest.* 104:439–446.
- Kern, B., J. Shen, M. Starbuck, and G. Karsenty. 2001. *Cbfa1* contributes to the osteoblast-specific expression of type I collagen genes. *J. Biol. Chem.* 276:7101–7107.
- Kitazawa, R., S. Kitazawa, and S. Maeda. 1999. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. *Biochim. Biophys. Acta.* 1445:134–141.
- Kobayashi, H., Y.-H. Gao, C. Ueta, A. Yamaguchi, and T. Komori. 2000. Multi-lineage differentiation of *Cbfa1*-deficient calvarial cells in vitro. *Biochem. Biophys. Res. Commun.* 273:630–636.
- Komori, T., and T. Kishimoto. 1998. *Cbfa1* in bone development. *Curr. Opin. Genet. Dev.* 8:494–499.
- Komori, T., H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.-H. Gao, M. Inada, et al. 1997. Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell.* 89:755–764.
- Krebsbach, P.H., J.R. Harrison, A.C. Lichtler, C.O. Woody, D.W. Rowe, and B.E. Kream. 1993. Transgenic expression of COL1A1-chloramphenicol acetyltransferase fusion genes in bone: differential utilization of promoter elements in vivo and in cultured cells. *Mol. Cell. Biol.* 13:5168–5174.
- Lee, K.S., H.J. Kim, Q.L. Li, X.Z. Chi, C. Ueta, T. Komori, J.M. Wozney, E.G. Kim, J.Y. Choi, H.M. Ryoo, et al. 2000. Runx2 is a common target of transforming growth factor β 1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. *Mol. Cell. Biol.* 20:8783–8792.
- Levanon, D., R.E. Goldstein, Y. Bernstein, H. Tang, D. Goldernberg, S. Stifani, Z. Paroush, and Y. Groner. 1998. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. *Proc. Natl. Acad. Sci. USA.* 95:11590–11595.
- Lutterbach, B., J.J. Westendorf, B. Linggi, S. Isaac, E. Seto, and S.W. Hiebert. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. *J. Biol. Chem.* 275:651–656.
- Manolagas, S.C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocr. Rev.* 21:115–137.
- Mark, M.P., W.T. Butler, C.W. Prince, R.D. Finkelman, and J.V. Ruch. 1988. Developmental expression of 44-kDa bone phosphoprotein (osteopontin) and bone γ -carboxyglutamic acid (Gla)-containing protein (osteocalcin) in calcifying tissues of rat. *Differentiation.* 37:123–136.
- Mundlos, S., F. Otto, C. Mundlos, J.B. Mulliken, A.S. Aylsworth, S. Albright, D. Lindhout, W.G. Cole, W. Henn, J.H.M. Knoll, et al. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell.* 89:773–779.
- Nijweide, P.J., E.H. Burger, J. Klein Nulend, and A. Van der Plas. 1996. The osteocyte. In *Principles of Bone Biology*. J.P. Bilezikian, L.G. Raisz, and G.A. Rodan, editors. Academic Press, London, UK. 115–126.
- Otto, F., A.P. Thornell, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, G.W.H. Stamp, R.S.P. Beddington, S. Mundlos, B.R. Olsen, et al. 1997. *Cbfa1*, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell.* 89:765–771.
- Parfitt, A.M., M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier, S.M. Ott, and R.R. Recker. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. *J. Bone Miner. Res.* 2:595–610.
- Prince, M., C. Banerjee, A. Javed, J. Green, J.B. Lian, G.S. Stein, P.V. Bodine, and B.S. Komm. 2001. Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. *J. Cell Biochem.* 80:424–440.
- Rosser, J., H. Eberspaecher, and B. de Crombrughe. 1995. Separate cis-acting DNA elements of the mouse pro- α 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. *J. Cell Biol.* 129:1421–1432.
- Sato, M., E. Morii, T. Komori, H. Kawahata, M. Sugimoto, K. Terai, H. Shimizu, T. Yasui, H. Ogihara, N. Yasui, et al. 1998. Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. *Oncogene.* 17:1517–1525.
- Selvamurugan, N., M.R. Pulumati, D.R. Tyson, and N.C. Partridge. 2000. Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor α 1. *J. Biol. Chem.* 275:5037–5042.
- Stein, G.S., J.B. Lian, and T.A. Owen. 1990. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. *FASEB J.* 4:3111–3123.
- Thirunavukkarasu, K., D.L. Halladay, R.R. Miles, X. Yang, R.J. Galvin, S. Chandrasekhar, T.J. Martin, and J.E. Onyia. 2000. The osteoblast-specific transcription factor *Cbfa1* contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. *J. Biol. Chem.* 275:25163–25172.
- Ueta, C., M. Iwamoto, N. Kanatani, C. Yoshida, Y. Liu, M. Enomoto-Iwamoto, T. Ohmori, H. Enomoto, K. Nakata, K. Takada, et al. 2001. Skeletal malformations caused by overexpression of *Cbfa1* or its dominant negative form in chondrocytes. *J. Cell Biol.* 153:87–99.
- Weinreb, M., D. Shinar, and G.A. Rodan. 1990. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. *J. Bone Miner. Res.* 5:831–842.
- Xiao, Z.S., T.K. Hinson, and L.D. Quarles. 1999. *Cbfa1* isoform overexpression upregulates osteocalcin gene expression in non-osteoblastic and pre-osteoblastic cells. *J. Cell Biochem.* 74:596–605.
- Yamaguchi, A., T. Komori, and T. Suda. 2000. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and *Cbfa1*. *Endocr. Rev.* 21:393–411.
- Yoon, K., R. Buenaga, and G.A. Rodan. 1987. Tissue specificity and developmental expression of rat osteopontin. *Biochem. Biophys. Res. Commun.* 148:1129–1136.
- Young, M.F., K. Ibaraki, J.M. Kerr, and A.M. Heegaard. 1993. Molecular and cellular biology of the major noncollagenous proteins in bone. In *Cellular and Molecular Biology of Bone*. M. Noda, editor. Academic Press, London, UK. 191–234.